Macular degeneration
Therapeutic area
Neurology
Rare disease
No
- Definition
- Loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Macular degeneration
- Therapeutic area
- Neurology
- macular degeneration
- macula lutea retinal degeneration
- macula retinal degeneration
- retinal degeneration of macula lutea
- Severity
- Severe
- Neurology
- Ophthalmology
- MONDO ID
- MONDO:0003004
- Parent condition
- MONDO:0004580
Related records
Broader conditions (9)
- Disease
- Disease by body system or component
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Human disease
- Nervous system disorder
- Retinal degeneration
- Retinal disorder
Narrower conditions (47)
- Adult-onset foveomacular vitelliform dystrophy
- Age related macular degeneration 1
- Age related macular degeneration 10
- Age related macular degeneration 11
- Age related macular degeneration 12
- Age related macular degeneration 14
- Age related macular degeneration 2
- Age related macular degeneration 4
- Age related macular degeneration 6
- Age related macular degeneration 7
- Age related macular degeneration 8
- Age related macular degeneration 9
- Age-related macular degeneration
- Autosomal recessive bestrophinopathy
- Basal laminar drusen
- Cystoid macular edema
- Cystoid macular retinal degeneration
- Degeneration of macula and posterior pole
- Doyne honeycomb retinal dystrophy
- Dry age related macular degeneration
Trials (1,166)
- " En Face " OCT's Contribution in the Detection of Macular Retinal Toxicity Signs Linked to the Chronic Treatment of Synthetic Antimalarials
- "My Eyes, My Light": Amar Chokh, Amar Alo
- "Night Vision and Carotenoids"
- "Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally" Study
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
- 30g vs 33g Needle for Intravitreal Injections
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
- A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
- A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Approved drugs (1)
- Verteporfin
Drugs in development (47)
- Abicipar pegol Phase 3
- Aflibercept Phase 3
- AL-78898A Phase 2
- Albumin human Phase 2
- Alprostadil Phase 3
- Anecortave acetate Phase 3
- Ascorbic acid Phase 3
- Aspirin Phase 3
- Avacincaptad pegol Phase 3
- Avacincaptad pegol sodium Phase 2
- Beta carotene Phase 3
- Bevacizumab Phase 3
- Bevasiranib Phase 3
- Burixafor Phase 2
- Carotuximab Phase 2
- CDX-1135 Phase 1
- Celecoxib Phase 3
- Ciliary neurotrophic factor Phase 2
- Disitertide Phase 2
- Doconexent Phase 1
Other linked drugs (3)
- Brolucizumab
- Rifapentine
- Risuteganib